Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.

ABSTRACT: Radiotherapy shows excellent local control in liver cancers but carries the risk of radiation-induced liver dysfunction and liver failure. We conducted a study of plasma hepatocyte growth factor (HGF) in a clinical trial of proton radiotherapy in patients with unresectable liver cancers (NCT00976898), and in an observational study for liver cancer patients undergoing surgical treatments. Liver dysfunction within 3 months after radiotherapy-a Childs-Turcotte-Pugh (CTP) score increase of 1 point or more-occurred in 9/34 (26%) of patients. Patients with no increase in CTP score had lower pretreatment plasma HGF level (p?=?0.015). Both the increase in CTP score (p?=?0.034) and the pretreatment plasma HGF (p?=?0.017) were associated with OS. Plasma HGF was significantly associated with presence of cirrhosis (p?=?0.0027) and with Model for End-stage Liver Disease (MELD) score (p?

SUBMITTER: Hong TS 

PROVIDER: S-EPMC6194077 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature